Free Trial
NASDAQ:SPRC

SciSparc 4/29/2026 Earnings Report

SciSparc logo
$6.40 -0.52 (-7.45%)
As of 01:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

SciSparc EPS Results

Actual EPS
-$31.61
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

SciSparc Revenue Results

Actual Revenue
$0.20 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SciSparc Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

SciSparc Earnings Headlines

SciSparc (NASDAQ:SPRC) Shares Down 8.5% - What's Next?
Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX
The Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked America's #1 stock picker in 2020. He was mentored by two hedge fund billionaires from the Soros network and trained at Caltech. His readers have had the chance to see gains as high as AMD +8,500%... Nvidia +5,000%... Tesla +3,500%... Palantir +1,000%... and Apple +890%.tc pixel
See More SciSparc Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SciSparc? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SciSparc and other key companies, straight to your email.

About SciSparc

SciSparc (NASDAQ:SPRC) AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function. By harnessing acoustic pressure waves, the TR100 aims to promote neurogenesis and synaptic plasticity without the need for surgical intervention. SciSparc has obtained CE marking for its tSWS platform in the European Union and is actively pursuing clinical trials in indications such as post‐stroke motor rehabilitation, treatment‐resistant depression and other neurological disorders.

Serving both European and North American markets, SciSparc collaborates with academic institutions and clinical research centers to validate safety and efficacy in human subjects. Its Swiss headquarters oversees research and development, regulatory affairs and manufacturing partnerships, while its U.S. operations concentrate on clinical development and market access strategies. By integrating neuroscience research with advanced engineering, SciSparc aims to expand the availability of noninvasive neuromodulation therapies on a global scale.

View SciSparc Profile